1. Home
  2. LEU vs XERS Comparison

LEU vs XERS Comparison

Compare LEU & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Centrus Energy Corp.

LEU

Centrus Energy Corp.

N/A

Current Price

$89.65

Market Cap

1.9B

Sector

Industrials

ML Signal

N/A

XERS

Xeris Biopharma Holdings Inc.

N/A

Current Price

$16.62

Market Cap

1.8B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
LEU
XERS
Founded
1998
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Mining & Quarrying of Nonmetallic Minerals (No Fuels)
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
1.8B
IPO Year
1998
2021

Fundamental Metrics

Financial Performance
Metric
LEU
XERS
Price
$89.65
$16.62
Analyst Decision
Buy
Strong Buy
Analyst Count
21
7
Target Price
★ $180.00
$17.29
AVG Volume (30 Days)
730.7K
★ 2.9M
Earning Date
11-04-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 100.00
EPS
★ 2.63
N/A
Revenue
★ $193,000,000.00
$49,590,000.00
Revenue This Year
$6.14
$37.58
Revenue Next Year
$7.34
$31.16
P/E Ratio
$35.66
★ N/A
Revenue Growth
N/A
★ 142.67
52 Week Low
$84.86
$5.25
52 Week High
$345.60
$17.28

Technical Indicators

Market Signals
Indicator
LEU
XERS
Relative Strength Index (RSI) 36.68 78.36
Support Level $84.86 $5.90
Resistance Level $117.45 N/A
Average True Range (ATR) 8.44 0.73
MACD 0.25 0.26
Stochastic Oscillator 17.38 88.75

Price Performance

Historical Comparison
LEU
XERS

About LEU Centrus Energy Corp.

Centrus Energy Corp is engaged in the supply of nuclear fuel and services for the nuclear power industry. It operates through the Low-Enriched Uranium (LEU) and Technical Solutions segments. The LEU segment has two components which include the sale of separative work units and uranium. The Technical Solutions segment provides engineering, design, and manufacturing services to government and private sector customers. The majority of the firm's revenue is derived from the LEU segment. It has a business presence in the U.S. and other countries, of which prime revenue is generated in the U.S.

About XERS Xeris Biopharma Holdings Inc.

Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.

Share on Social Networks: